Xilio Therapeutics, Inc.
XLO
$8.46
-$0.05-0.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.69M | 19.07M | 8.08M | 2.93M | 1.72M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.69M | 19.07M | 8.08M | 2.93M | 1.72M |
| Cost of Revenue | -37.92M | 14.32M | 15.33M | -- | -32.38M |
| Gross Profit | 51.60M | 4.75M | -7.25M | 2.93M | 34.10M |
| SG&A Expenses | 7.40M | 6.67M | 7.12M | 8.52M | 6.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.52M | 21.00M | 22.45M | 16.78M | 15.35M |
| Operating Income | -11.84M | -1.93M | -14.37M | -13.85M | -13.63M |
| Income Before Tax | 10.36M | -16.29M | -15.84M | -13.27M | -13.09M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.36M | -16.29M | -15.84M | -13.27M | -13.09M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.36M | -16.29M | -15.84M | -13.27M | -13.09M |
| EBIT | -11.84M | -1.93M | -14.37M | -13.85M | -13.63M |
| EBITDA | -11.51M | -1.59M | -13.99M | -13.35M | -13.25M |
| EPS Basic | 0.96 | -4.40 | -4.28 | -2.49 | -2.83 |
| Normalized Basic EPS | 0.60 | -2.75 | -2.67 | -1.55 | -1.77 |
| EPS Diluted | 0.96 | -4.40 | -4.28 | -2.49 | -2.83 |
| Normalized Diluted EPS | 0.60 | -2.75 | -2.67 | -1.55 | -1.77 |
| Average Basic Shares Outstanding | 10.84M | 3.70M | 3.70M | 5.34M | 4.62M |
| Average Diluted Shares Outstanding | 10.84M | 3.70M | 3.70M | 5.34M | 4.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |